Immunoclin (Immunoclin) Cash And Cash Equivalents : $0.15 Mil (As of Oct. 2014)

View and export this data going back to 2012. Start your Free Trial

What is Immunoclin Cash And Cash Equivalents?

Immunoclin's quarterly cash and cash equivalents increased from Apr. 2014 ($0.09 Mil) to Jul. 2014 ($0.10 Mil) and increased from Jul. 2014 ($0.10 Mil) to Oct. 2014 ($0.15 Mil).

Immunoclin's annual cash and cash equivalents increased from Feb. 2012 ($0.01 Mil) to Jan. 2013 ($0.17 Mil) but then declined from Jan. 2013 ($0.17 Mil) to Jan. 2014 ($0.05 Mil).

Immunoclin Cash And Cash Equivalents Historical Data

The historical data trend for Immunoclin's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunoclin Cash And Cash Equivalents Chart

Immunoclin Annual Data

Trend

Feb12

Jan13

Jan14

Cash And Cash Equivalents

0.01

0.17

0.05

Immunoclin Quarterly Data
	May11	Aug11	Nov11	Feb12	May12	Aug12	Nov12	Feb13	May13	Aug13	Nov13	Apr14	Jul14	Oct14
Cash And Cash Equivalents	Get a 7-Day Free Trial									-	-	0.09	0.10	0.15

Immunoclin Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Immunoclin (GREY:IMCL) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Immunoclin Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Immunoclin's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunoclin (Immunoclin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunoclin Corp (GREY:IMCL) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

9107 Wilshire Boulevard, Suite 450, Beverly Hills, CA, USA, 90210

Website

http://www.immunoclin.com

Immunoclin Corp is engaged in immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Immunoclin (Immunoclin) Headlines

No Headlines